MedTrace Logo

Risk of Chronic Diseases in Young Adults Born Preterm: Relationship With Inflammation and Oxidative Stress Biomarkers.

NCT03261609 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-11-03

No results posted yet for this study

Summary

The purpose of the HAPI project is to study the overall health of preterm infants once they reach adulthood. The investigators would like to compare the health of adults born preterm with that of adults born full-term. They would also like to find the early signs, or biomarkers, of chronic diseases such as high blood pressure, diabetes, osteoporosis, and chronic lung diseases.

Such biomarkers would allow for early diagnosis and prevention. Furthermore, the investigators would like to understand why some people born preterm are more likely to develop chronic disease. They believe that inflammation and oxidative stress may play a part. Oxidative stress is present when the body is not able to defend itself against oxygen-derived products that can damage our cells.

To carry out this study, the investigators will examine 6 aspects of the health: (1) heart and circulation, (2) kidneys, (3) lungs, (4) metabolism - sugars and fats in the blood, (5) bones, and (6) eyes.

Conditions

  • Prematurity; Extreme

Interventions

OTHER

preterm birth

The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)

Sponsors & Collaborators

  • Jewish General Hospital

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER

  • St. Justine's Hospital

    lead OTHER

Principal Investigators

  • Anne Monique Nuyt, MD · St. Justine's Hospital

  • Thuy Mai Luu, MD · St. Justine's Hospital

Eligibility

Min Age
18 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-01
Primary Completion
2017-03-29
Completion
2017-04-29

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03261609 on ClinicalTrials.gov